Selux Diagnostics has received an award from the US National Institutes of Health (NIH) to help commercialize its next generation phenotyping (NGP) platform for rapid antimicrobial susceptibility testing (AST). Having recently completed its first clinical trial and submitted the results to the US FDA, the NIH grant will be used to fund three projects that advance the commercial readiness of the NGP platform. This NGP technology works for all sample types and utilizes phenotypic AST, providing full results that indicate which therapies can effectively treat a patient’s infection. With a comprehensive antibiotic menu, NGP can provide accurate, same-shift results for up to 50 antibiotics simultaneously. As a result, physicians can prescribe optimal treatment 3 to 5 days sooner, reducing hospital stays and de-escalating the cycle of antibiotic overuse and resistance.